REFERENCES
1. Ghosh TS, Shanahan F, O'Toole PW. The gut microbiome as a modulator of healthy ageing. Nat Rev Gastroenterol Hepatol. 2022;19:565-84.
2. Karu N, Deng L, Slae M, et al. A review on human fecal metabolomics: Methods, applications and the human fecal metabolome database. Anal Chim Acta. 2018;1030:1-24.
3. Chen MX, Wang SY, Kuo CH, Tsai IL. Metabolome analysis for investigating host-gut microbiota interactions. J Formos Med Assoc. 2019;118 Suppl 1:S10-22.
4. Pope R, Visconti A, Zhang X, et al. Faecal metabolites as a readout of habitual diet capture dietary interactions with the gut microbiome. Nat Commun. 2025;16:10051.
5. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293-305.
6. Vich Vila A, Hu S, Andreu-Sánchez S, et al. Faecal metabolome and its determinants in inflammatory bowel disease. Gut. 2023;72:1472-85.
7. Vich Vila A, Zhang J, Liu M, Faber KN, Weersma RK. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases. Gut. 2024;73:1909-20.
8. Yasuda S, Okahashi N, Tsugawa H, et al. Elucidation of Gut Microbiota-Associated Lipids Using LC-MS/MS and 16S rRNA Sequence Analyses. iScience. 2020;23:101841.
9. Wei R, Li G, Seymour AB. High-throughput and multiplexed LC/MS/MRM method for targeted metabolomics. Anal Chem. 2010;82:5527-33.
10. Lu W, Bennett BD, Rabinowitz JD. Analytical strategies for LC-MS-based targeted metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;871:236-42.
11. Sarmad S, Viant MR, Dunn WB, et al. ; UK Consortium on Metabolic Phenotyping (MAP/UK). A proposed framework to evaluate the quality and reliability of targeted metabolomics assays from the UK Consortium on Metabolic Phenotyping (MAP/UK). Nat Protoc. 2023;18:1017-27.
12. Ribbenstedt A, Ziarrusta H, Benskin JP. Development, characterization and comparisons of targeted and non-targeted metabolomics methods. PLoS ONE. 2018;13:e0207082.
13. Costea PI, Zeller G, Sunagawa S, et al. Towards standards for human fecal sample processing in metagenomic studies. Nat Biotechnol. 2017;35:1069-76.
14. Mori H, Maruyama T, Yano M, Yamada T, Kurokawa K. VITCOMIC2: visualization tool for the phylogenetic composition of microbial communities based on 16S rRNA gene amplicons and metagenomic shotgun sequencing. BMC Syst Biol. 2018;12 Suppl:30.
15. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41-50.
16. Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21:236-47.
17. Pang Z, Chong J, Zhou G, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49:W388-96.
18. Wakita Y, Shimomura Y, Kitada Y, Yamamoto H, Ohashi Y, Matsumoto M. Taxonomic classification for microbiome analysis, which correlates well with the metabolite milieu of the gut. BMC Microbiol. 2018;18:188.
19. Schwaiger-Haber M, Stancliffe E, Arends V, Thyagarajan B, Sindelar M, Patti GJ. A workflow to perform targeted metabolomics at the untargeted scale on a triple quadrupole mass spectrometer. ACS Meas Sci Au. 2021;1:35-45.
20. Zheng X, Qiu Y, Zhong W, et al. A targeted metabolomic protocol for short-chain fatty acids and branched-chain amino acids. Metabolomics. 2013;9:818-27.
21. Liao Z, Zhang S, Liu W, et al. LC-MS-based metabolomics analysis of Berberine treatment in ulcerative colitis rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1133:121848.
22. Nagatomo R, Okada Y, Ichimura M, Tsuneyama K, Inoue K. Application of 2-picolylamine derivatized ultra-high performance liquid chromatography tandem mass spectrometry for the determination of short-chain fatty acids in feces samples. Anal Sci. 2018;34:1031-6.
23. Li H, Liu Y, Zhang X, et al. Medium-chain fatty acids decrease serum cholesterol via reduction of intestinal bile acid reabsorption in C57BL/6J mice. Nutr Metab (Lond). 2018;15:37.
24. Matsumoto M, Kunisawa A, Hattori T, et al. Free D-amino acids produced by commensal bacteria in the colonic lumen. Sci Rep. 2018;8:17915.
25. Song Y, Song Q, Li J, et al. An integrated platform for directly widely-targeted quantitative analysis of feces part II: an application for steroids, eicosanoids, and porphyrins profiling. J Chromatogr A. 2016;1460:74-83.
26. Matsumoto M, Kibe R, Ooga T, et al. Impact of intestinal microbiota on intestinal luminal metabolome. Sci Rep. 2012;2:233.
27. Ling CW, Miao Z, Xiao ML, et al. The association of gut microbiota with osteoporosis is mediated by amino acid metabolism: multiomics in a large cohort. J Clin Endocrinol Metab. 2021;106:e3852-64.
28. Mishima E, Fukuda S, Mukawa C, et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 2017;92:634-45.
29. Deda O, Virgiliou C, Orfanidis A, Gika HG. Study of fecal and urinary metabolite perturbations induced by chronic ethanol treatment in mice by UHPLC-MS/MS targeted profiling. Metabolites. 2019;9:232.
30. Trošt K, Ahonen L, Suvitaival T, et al. Describing the fecal metabolome in cryogenically collected samples from healthy participants. Sci Rep. 2020;10:885.
31. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017;19:29-41.
32. Nagatake T, Kunisawa J. Emerging roles of metabolites of ω3 and ω6 essential fatty acids in the control of intestinal inflammation. Int Immunol. 2019;31:569-77.
33. Hudson JA, Morvan B, Joblin KN. Hydration of linoleic acid by bacteria isolated from ruminants. FEMS Microbiol Lett. 1998;169:277-82.
34. Kishino S, Takeuchi M, Park SB, et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc Natl Acad Sci U S A. 2013;110:17808-13.
35. Miyamoto J, Mizukure T, Park SB, et al. A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem. 2015;290:2902-18.
36. Simopoulos AP. An Increase in the Omega-6/Omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016;8:128.
37. Shinohara M, Serhan CN. Novel endogenous proresolving molecules: essential fatty acid-derived and gaseous mediators in the resolution of inflammation. J Atheroscler Thromb. 2016;23:655-64.
38. Ungaro F, Rubbino F, Danese S, D'Alessio S. Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. Front Immunol. 2017;8:1331.
39. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015;27:200-15.
40. Jaén RI, Sánchez-García S, Fernández-Velasco M, Boscá L, Prieto P. Resolution-based therapies: the potential of lipoxins to treat human diseases. Front Immunol. 2021;12:658840.
41. Zhao Z, Ning J, Bao XQ, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021;9:226.
42. Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70:761-74.
